Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CLRB stock hub

Cellectar Biosciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

CLRBis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
13.1M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
CLRB
In the news

Latest news · CLRB

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROE-170.3
P25 -105.6P50 -46.5P75 -3.1
ROIC-108.4
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All CLRB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
182
Groups with data
11
Currency
USD
Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

23
MetricValue
Cik
0001279704
Company name
Cellectar Biosciences, Inc.
Country
United States
Country code
US
Cusip
15117F880
Employees
11
Employees Change
-9%
Employees Change Percent
-45
Enterprise value
$357,953
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
Isin
US15117F8804
Last refreshed
2026-05-10
Market cap
$13.1M
Market cap category
Nano-Cap
Price
$3.1
Price currency
USD
Sector
Healthcare
Sic
2834
Symbol
CLRB
Website
https://www.cellectar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

3
MetricValue
Earnings Yield
-165.78%
FCF yield
-175.92%
P/B ratio
1.64x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

8
MetricValue
Net Income
$-21.8M
Net Income Growth Years
1%
Profit Per Employee
$-2M
ROA
-71.01
Roa5y
-96.15
ROCE
-224.7
ROE
-170.3
ROIC
-108.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

7
MetricValue
Cagr10y
-51.82%
Cagr15y
-56.55%
Cagr1y
-57.71%
Cagr3y
-58.63%
Cagr5y
-62.32%
EPS Growth Years
3
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

17
MetricValue
Assets
$15M
Cash
$13.2M
Current Assets
$14M
Current Liabilities
$4.7M
Debt
$409,586
Debt Equity
$0.04
Equity
$9.9M
Liabilities
$5.1M
Long Term Assets
$939,856
Long Term Liabilities
$309,397
Net Cash
$12.8M
Net Cash By Market Cap
$97.28
Net Cash Growth
-43.91%
Net Debt Equity
$-1.29
Tangible Book Value
$8M
Tangible Book Value Per Share
$1.89
WACC
6.41

Liquidity

Current-asset coverage and working-capital efficiency metrics.

4
MetricValue
Current ratio
2.96
Net Working Capital
$-3.8M
Quick ratio
2.78
Working Capital
$9.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-110.67%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

42
MetricValue
10Y total return
-99.93%
1Y total return
-57.68%
200-day SMA
3.74
3Y total return
-92.92%
50-day SMA
2.91
50-day SMA vs 200-day SMA
50under200
5Y total return
-99.24%
All Time High
1,799,964
All Time High Change
-100%
All Time High Date
2011-04-11
All Time Low
2.43
All Time Low Change
27.57%
All Time Low Date
2026-04-01
ATR
0.35
Beta
0.43
Beta1y
0.66
Beta2y
1.08
Ch YTD
5.09
High
3.23
High52
20.6
High52 Date
2025-06-04
High52ch
-84.95%
Low
2.88
Low52
2.43
Low52 Date
2026-04-01
Low52ch
27.57%
Ma50ch
6.68%
Premarket Change Percent
-2.73
Premarket Price
$3.21
Premarket Volume
27,490
Price vs 200-day SMA
-17.07%
RSI
55.26
RSI Monthly
26.91
RSI Weekly
43.05
Sharpe ratio
-0.24x
Sortino ratio
-0.32
Total Return
-110.67%
Tr YTD
5.09
Tr15y
-100%
Tr1m
12.73%
Tr1w
15.24%
Tr3m
1.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

6
MetricValue
Analyst Count
1
Analyst Ratings
Strong Buy
Earnings EPS Estimate
$-1.78
Operating Income
$-23M
Price target
$10
Price Target Change
$223

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

10
MetricValue
Float
4,084,147%
Float Percent
96.32%
Shares Insiders
3.68%
Shares Institutions
12.29%
Shares Out
4,240,129
Shares Qo Q
29.93%
Shares Yo Y
110.67%
Short Float
0.67%
Short Ratio
0.83
Short Shares
0.64

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

60
MetricValue
Adjusted FCF
$-25.4M
Average Volume
2,892,829x
Bv Per Share
1.89
CAPEX
$-5,880
Ch10y
-99.93
Ch15y
-100
Ch1m
12.73
Ch1w
15.24
Ch1y
-57.68
Ch3m
1.97
Ch3y
-92.92
Ch5y
-99.24
Ch6m
-8.55
Change
-6.06%
Change From Open
-3.43
Close
3.3
Days Gap
-2.73
Depreciation Amortization
213,597
Dollar Volume
2,130,574.2
Earnings Date
2026-05-22
Earnings Time
bmo
EBIT
$-23M
EBITDA
$-22.8M
EPS
$-8.35
F Score
1
FCF
$-23.1M
FCF EV Yield
-6,460.09x
FCF Per Share
$-5.45
Financing CF
13,031,523
Fiscal Year End
December
Founded
2,002
Investing CF
-5,880
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-03-04
Last Report Date
2025-12-31
Last Split Date
2025-06-24
Last Split Type
Reverse
Last10k Filing Date
2026-03-04
Ma150
3.32
Ma150ch
-6.68%
Ma20
2.89
Ma20ch
7.19%
Net CF
-10,092,574
Next Earnings Date
2026-05-22
Open
3.21
Optionable
No
Position In Range
62.86
Post Close
3.1
Postmarket Change Percent
-2.9
Postmarket Price
$3.01
Ppne
910,076
Pre Close
3.3
Price Date
2026-05-08
Ptbv Ratio
1.64
Relative Volume
0.24x
Share Based Comp
2,263,704
Tr6m
-8.55%
Us State
New Jersey
Volume
687,282
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does CLRB pay a dividend?

Capital-return profile for this ticker.

Performance

CLRB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
-57.7%
S&P 500 1Y: n/a
3Y total return
-92.9%
S&P 500 3Y: n/a
5Y total return
-99.2%
S&P 500 5Y: n/a
10Y total return
-99.9%
S&P 500 10Y: n/a
Ownership

Who owns CLRB?

Insider, institutional, and short-interest positioning.

Institutional ownership
+12.3%
Float: +96.3% of shares outstanding
Insider ownership
+3.7%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+0.7%
0.8 days to cover
Y/Y dilution
+110.7%
Negative means the company is buying back shares.
Technical

CLRB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
55.3
Neutral momentum band
Price vs 200-day MA
-17.1%
50/200-day relationship not available
Beta (5Y)
0.43
Less volatile than the market
Sharpe ratio
-0.24
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About CLRB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CLRB stock rating?

Cellectar Biosciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CLRB analysis?

The full report lives at /stocks/CLRB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CLRB?

The latest report frames CLRB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CLRB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.